Please ensure Javascript is enabled for purposes of website accessibility

Live: Coronavirus Market Crash Coverage

The Motley Fool’s live guide on what investors should do during the stock market crash and the COVID-19 pandemic.

We’ve created this page for all investors seeking advice on what they should be doing in this turbulent period. Our most important content can be found in the Editors' Picks, section.

We do believe this will all end up behind us, because we view investing as a long-term endeavor. Borrowing from Warren Buffett: "We have no idea -- and never have had -- whether the market is going to go up, down, or sideways in the near- or intermediate-term future." However, we firmly believe investors will be rewarded over the long term.

We suggest bookmarking this page as we will update our Editors' Picks periodically -- the Recent Articles section is a live feed of our latest thinking. Finally, we understand that many people are seeking epidemiological information on COVID-19. For that we strictly suggest visiting the information pages set up by the CDC and WHO.

For members of The Motley Fool's investing services, you can access all our Coronavirus market coverage at fool.com/premium after logging in.

Recent articles

GettyImages-142018923

Disney or Macy's: Which Is Closer to Restarting Dividend Payments?

Disney and Macy's are probably thanking their lucky stars that business is recovering, but are they ready to restart dividends?


Vaccine bottles forming a dollar sign

Why Moderna Just Booked Another $3 Billion in Vaccine Orders and No One Cared

Investors seemed to yawn over a really big new deal for the vaccine maker.


GettyImages-1294483101

Is Now the Time to Go All-In On Novavax Stock?

This coronavirus vaccine developer is near the finish line to the already-decided vaccine race.


Coronavirus with earth inside it

Why Pfizer's About to Sell 500 Million COVID Vaccine Doses Without Making a Dime

The big drugmaker's bottom line won't be helped, but millions of people across the world will.


COVID vaccine - female healthcare professional

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

The declines appear to be caused simply by volatility that's common with small biotech stocks.


Vaccine being given to young man

How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?

It's way too early to worry.


Head on keyboard behind laptop screen

Ocugen Stock Crashes: What Should Investors Do Now?

Here are three steps to take.


COVID vaccine vial and syringe, India flag

Why Pfizer and Moderna Could Soon Be Big Winners in a New $22 Billion Market

The market size could even be bigger. But the drugmakers still have some hurdles to jump.


GettyImages-1216332497

What's Behind This Wild-Card Coronavirus Stock?

Failure is not an option for this small-cap biotech developing a COVID-19 treatment.


gettyimages-1232146964-594x594

How Did Moderna's COVID Vaccine Results in Teens Stack Up Against Pfizer's?

Pretty well, although it's not an apples-to-apples comparison between the two studies.


GettyImages-601798527

Could COVID Vaccination Incentives Hint at Future Problems for Pfizer and Moderna?

The need for incentives for vaccination now could point to lower vaccination rates going forward.


GettyImages-1266646735

Down 50%, Is Novavax Stock a Great Buy Now?

This coronavirus vaccine drugmaker is having trouble getting its act together -- and has led its investors on a wild ride.


Scientists holding vaccine bottle

Did the FDA Slam the Door on Ocugen's Chances of Winning Authorization for Covaxin?

The agency's revised emergency-authorization guidance for COVID-19 vaccines appears to present a significant hurdle for Ocugen.


Coronavirus and chart images

This Ominous Warning From Moderna Could Shake Up the COVID Vaccine Market

The pandemic isn't over yet -- even in the U.S.


Vaccine vials with shopping cart

2 Reasons to Avoid Ocugen Stock -- and 1 Reason to Consider Buying It

The company has a path to success in the COVID-19 vaccine market, but it might be more of an uphill climb than some investors realize.


Vaccine syringe with $100 bill in it

Are Pfizer and Moderna Trying to Boost Sales With an Early COVID Booster Shot?

It's a definite maybe.


Vaccine bottles forming a dollar sign

Could This Study Be Bad News for Pfizer's COVID Vaccine Sales?

It might seem bad at first glance.


COVID vaccine - female healthcare professional

The Top Reason Novavax Could Still Be a Huge Winner in the COVID-19 Vaccine Market

It could even be the most likely to succeed.


Reputation gauge

Here's 1 Surprising Ranking Where Moderna Handily Beats Pfizer

The biotech came out of nowhere to vault near the top of this survey ranking.


Vaccine shot

Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?

It's still really early.